Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer

Fasching, Peter A.; Decker, Thomas; Hartkopf, Andreas; Nusch, Arnd; Heinrich, Bernhard J.; Kurbacher, Christian; Fuchs, Roswitha; Tesch, Hans; Krabisch, Petra; Huober, Jens; Kuemmel, Sherko; Brucker, Sara; Janni, Wolfgang; Schneeweiss, Andreas; Schuler, Martin; Fehm, Tanja; Lueftner, Diana; Quiering, Claudia; Voges, Claudia; Kreuzeder, Julia; Reinisch, Mattea

Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer

Autor(en):

Fasching, Peter A.; Decker, Thomas; Hartkopf, Andreas; Nusch, Arnd; Heinrich, Bernhard J.; Kurbacher, Christian; Fuchs, Roswitha; Tesch, Hans; Krabisch, Petra; Huober, Jens; Kuemmel, Sherko; Brucker, Sara; Janni, Wolfgang; Schneeweiss, Andreas; Schuler, Martin; Fehm, Tanja; Lueftner, Diana; Quiering, Claudia; Voges, Claudia; Kreuzeder, Julia; Reinisch, Mattea

Tübinger Autor(en):

Hartkopf, Andreas
Brucker, Sara

Erschienen in:

European Journal of Cancer (2024), Bd. 198, Article 113480

Verlagsangabe:

London : Elsevier Sci Ltd

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1016/j.ejca.2023.113480

ISSN:

0959-8049